Detalles de la búsqueda
1.
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Clin Cancer Res
; 14(11): 3477-86, 2008 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18519780
2.
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.
J Hematol Oncol
; 10(1): 73, 2017 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28327200
3.
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Cancer Res
; 64(11): 3761-6, 2004 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15172981
4.
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Cancer Chemother Pharmacol
; 56(2): 154-60, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15809877
5.
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
Clin Cancer Res
; 10(10): 3265-72, 2004 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15161679
6.
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
Clin Cancer Res
; 10(21): 7220-8, 2004 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15534095
7.
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Clin Cancer Res
; 8(12): 3710-7, 2002 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-12473580
8.
Identification and characterization of the canine multidrug resistance-associated protein.
Mol Cancer Ther
; 1(14): 1335-42, 2002 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-12516967
9.
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Drug Des Devel Ther
; 9: 4479-99, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26309397
10.
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
Leuk Lymphoma
; 56(1): 42-8, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24717109
11.
Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters.
Biochem Pharmacol
; 67(6): 1111-21, 2004 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15006547
12.
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 71(6): 1645-55, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23616084
13.
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
Clin Cancer Res
; 18(5): 1395-403, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22223529
14.
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.
Cancer Chemother Pharmacol
; 68(5): 1233-41, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21431416
15.
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Clin Cancer Res
; 17(18): 6071-82, 2011 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21753156
16.
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.
Clin Cancer Res
; 16(24): 6150-8, 2010 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21041181
17.
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
J Clin Oncol
; 25(13): 1741-6, 2007 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17389337
18.
A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.
Int J Cancer
; 97(2): 149-56, 2002 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-11774257
Resultados
1 -
18
de 18
1
Próxima >
>>